Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
618.00    5.00 (0.82%)
Bid:
617.00
Ask:
619.00
Spread: 2.00 (0.324%)
Market Cap: £685.83m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Update

28 Jan 2025 07:00

RNS Number : 8582U
Barr(A.G.) PLC
28 January 2025
 

IMMEDIATE RELEASE 28 January 2025

A.G. BARR p.l.c

Trading Update

 

 Sustained revenue growth and double digit profit growth

A.G. BARR p.l.c., the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today announces a trading update for the full year ended 25 January 2025 (2024/25).

Revenue in 2024/25 is expected to be c.£420m (2023/24: £400m), representing c.5% year-on-year growth.

Full year adjusted operating margin is expected to show strong improvement to c.13.5% (2023/24:12.3%), helping to drive double digit profit1 growth.

Highlights

Soft Drinks:  All three core soft drinks brands - IRN-BRU, Rubicon and Boost - performed strongly. Rubicon was the stand-out performer, achieving another year of double digit revenue growth. IRN-BRU also delivered strong revenue growth and is now one of the top five carbonates in the UK. The Boost strategy, to focus on value over volume and synergy benefits, gained momentum in H2 with a step up in profitability. The brand is now fully integrated into our commercial operation and the insourcing of manufacturing remains on track.

FUNKIN: FUNKIN's ready-to-drink business continued to grow at pace through retail distribution gains and innovation. This went some way to mitigate on-going challenges within the on-premise market.

Strategic Programme: We have successfully completed the projects to strengthen our convenience channel route to market and integrate Boost into our Soft Drinks business. These projects deliver significant commercial and operational synergies. As previously advised, they give rise to a one-off cost of c.£5m in the 2024/25 financial year, which will be treated as an adjusting item.

Capital Investment:  The multi-year supply chain investment programme continues on plan, supporting brand growth, efficiency improvements and synergy benefits.  Overall capital spend in the year of c.£19m included a new small format PET line and an upgraded large format PET line at our Cumbernauld site, providing increased capacity and capability.

Balance Sheet & Cash Flow: We remain a highly cash generative business, ending the year with more than £60m of net cash (2023/24: £53.6m).

People: Our talent development continues with the roll-out of a refreshed employee development programme and we are pleased to have welcomed a new Chief Commercial Officer, Dino Labbate, who joined in January 2025.

 

Euan Sutherland, Chief Executive, commented:

"A.G. BARR is in line to deliver another year of strong top line growth, margin improvement and cash generation. These headline metrics highlight excellent progress towards our long-term financial goals. We have sustained brand momentum despite the well trailed wider market pressures, and continue to make good progress towards our margin target.

We are committed to consistent long-term revenue growth and have confidence in further margin improvement as per our previous guidance. Our expectations for 2025/26 are unchanged and in line with market expectations2."

Future Events

Full year results for 2024/25 year will be reported on 25 March 2025. In addition, the business plans to hold analyst and investor visits to its Cumbernauld and Milton Keynes sites in the spring and a Capital Markets event in June.

 

Proposed analyst and investor factory and market visit dates are as follows:

Cumbernauld 23 April 2025

Milton Keynes 15 May 2025

Notes

1 - adjusted profit before tax

2 - Analyst consensus:

● FY 2024/25: revenue £420.1m; adjusted PBT £57.4m; adjusted operating margin 13.4%

● FY 2025/26: revenue £439.4m; adjusted PBT £65.0m; adjusted operating margin 14.5%

Note: This is based on estimates of analysts who have updated forecasts over the past 6 months

 

For more information, please contact :

A.G. BARR Instinctif Partners

0330 390 3900 020 7457 2010/05

Euan Sutherland Chief Executive Justine Warren

Stuart Lorimer, Finance Director Matthew Smallwood

Hannah Scott

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPUQGGUPAGRM
Date   Source Headline
9th Jun 20262:00 pmRNSDirector/PDMR Shareholding
9th Jun 20262:00 pmRNSDirector/PDMR Shareholding
8th Jun 20263:00 pmRNSDirector/PDMR Shareholding
5th Jun 20261:00 pmRNSDirector/PDMR Shareholding
3rd Jun 20267:00 amRNS-RLaunch of IRN-BRU Summer Campaign
27th May 20263:00 pmRNSDirector/PDMR Shareholding
26th May 20261:30 pmRNSDirector/PDMR Shareholding
22nd May 20262:00 pmRNSResult of AGM
11th May 20262:46 pmRNSDirector/PDMR Shareholding
21st Apr 202610:43 amRNSAnnual Report and Accounts and Notice of AGM
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
13th Apr 20269:39 amRNSDirector/PDMR Shareholding
7th Apr 202611:21 amRNSDirector/PDMR Shareholding
1st Apr 20268:44 amRNSDirector/PDMR Shareholding
31st Mar 20267:00 amRNSFinal Results
23rd Mar 20267:00 amRNS-RLaunch of IRN-BRU 'ZERO'
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
3rd Mar 20267:00 amRNSNotice of Results Presentation
9th Feb 20263:56 pmRNSDirector/PDMR Shareholding
4th Feb 20264:16 pmRNSHolding(s) in Company
3rd Feb 20267:00 amRNSFull Year Trading Update
15th Jan 20267:00 amRNSDirectorate change
12th Jan 202611:00 amRNSDirector/PDMR Shareholding
8th Dec 20252:49 pmRNSDirector/PDMR Shareholding
19th Nov 20251:44 pmRNSHolding(s) in Company
17th Nov 20253:25 pmRNSDirector/PDMR Shareholding
10th Nov 20254:44 pmRNSDirector/PDMR Shareholding
10th Nov 20254:38 pmRNSDirector/PDMR Shareholding
8th Oct 20252:39 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSInterim Results
11th Sep 20252:00 pmRNSNotice of Results
10th Sep 20256:00 pmRNSDirector/PDMR Shareholding
28th Aug 20252:00 pmRNS2025 Annual General Meeting Update
12th Aug 20254:01 pmRNSDirector/PDMR Shareholding
1st Aug 20257:01 amRNSDirector Declaration
29th Jul 20257:00 amRNSTrading Statement
9th Jul 202511:00 amRNSAppointment of Non-Executive Director
8th Jul 20252:02 pmRNSDirector/PDMR Shareholding
3rd Jul 202511:09 amRNSDirector/PDMR Shareholding
11th Jun 202511:01 amRNSDirector/PDMR Shareholding
10th Jun 20254:20 pmRNSDirector/PDMR Shareholding
10th Jun 20252:02 pmRNSDirector/PDMR Shareholding
3rd Jun 20257:00 amRNSCapital Markets Event
23rd May 20255:36 pmRNSResult of AGM
12th May 20251:54 pmRNSDirector/PDMR Shareholding
30th Apr 20259:15 amRNSPotential disposal of Strathmore Business
28th Apr 20253:16 pmRNSDirector/PDMR Shareholding
28th Apr 20253:15 pmRNSDirector/PDMR Shareholding
22nd Apr 202510:24 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.